Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals
(KNSA)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Arcalyst
Rilonacept
2008-02-27
Inborn genetic diseases
,
Inflammation
,
Cryopyrin-associated periodic syndromes
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Mavrilimumab
respiratory insufficiency
,
sars-cov-2
,
severe acute respiratory syndrome-related coronavirus
,
giant cell arteritis
,
covid-19
,
pneumonia
,
inflammation
Rilonacept
hearing loss
,
deafness
,
juvenile arthritis
,
systemic scleroderma
,
localized scleroderma
,
diffuse scleroderma
,
sclerosis
,
chronic renal insufficiency
,
kidney diseases
,
anemia
,
gout
,
arthritis
,
inborn genetic diseases
,
metabolic diseases
,
rheumatic diseases
,
joint diseases
,
musculoskeletal diseases
,
inborn errors metabolism
,
inborn errors purine-pyrimidine metabolism
,
urticaria
,
cold urticaria
,
cryopyrin-associated periodic syndromes
,
syndrome
VIXARELIMAB
pruritus
,
ulcerative colitis
,
psoriasis
,
lichen planus
,
chronic urticaria
,
urticaria
,
neurodermatitis
,
prurigo
,
systemic scleroderma
,
idiopathic pulmonary fibrosis
,
gastrointestinal diseases
,
inflammatory bowel diseases
,
colitis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use